PEDMARK is gaining traction with doctors and large cancer centers, and the company is starting to push into more countries sooner than many expect. If that momentum holds, Fennec could grow much faster and reach steady profitability earlier, but it also hinges heavily on one product in a market facing pricing and copycat pressure.Read more
Key Takeaways Expanding into new patient segments and global markets is fueling strong revenue growth and increasing adoption of PEDMARK® through strategic partnerships and investments. Positive regulatory developments and operational efficiencies are expected to improve margins, enable further product expansion, and support a move toward sustainable profitability.Read more
Key Takeaways Heavy reliance on a single drug and exposure to pricing pressure threaten margin stability and make future revenue growth dependent on successful pipeline expansion. Expansion into new demographics and regions offers growth potential, but slow adoption, regulatory hurdles, and resource limits may restrain market penetration and earnings.Read more
Fennec Pharmaceuticals Inc. operates as a commercial stage biopharmaceutical company in the United States. The company’s product candidate includes PEDMARK, a formulation of sodium thiosulfate for the prevention of cisplatin-induced ototoxicity pediatric patients. It sells its products through regional pediatric oncology specialists and medical science liaisons. Fennec Pharmaceuticals Inc. has collaboration with Tampa General Hospital Foundation, Inc. for evaluation of clinical utility of sodium thiosulfate injection in reducing the risk of ototoxicity in adolescent, young adult, and adult cancer patients receiving cisplatin-based treatment; and Norgine Pharma UK Limited. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was incorporated in 1996 and is based in Research Triangle Park, North Carolina.
